Since second-generation ALK inhibitors, such as aletinib, brigatinib, and ensartinib, can increase progression free survival (PFS) compared to crizotinib, these latest-generation ALK inhibitors are suggested as first-line treatments for patients with ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.